Clinical Trial Update: Tocilizumab for Relapsing Polychondritis [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating tocilizumab for Relapsing Polychondritis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Polychondritis

Drugs mentioned

• Tocilizumab (tocilizumab)

Snippet

Sponsor: McMaster Children's Hospital | Conditions: Relapsing Polychondritis | Phase 2 | Status: WITHDRAWN